Lamisil is the brand name for the antifungal drug terbinafine, which belongs to the allylamine class. It is widely used for the treatment of superficial fungal infections, particularly those affecting the skin, hair, and nails. Terbinafine exerts its antifungal activity primarily by inhibiting the enzyme squalene epoxidase, a key step in the biosynthesis of ergosterol—an essential component of fungal cell membranes. The accumulation of squalene, combined with ergosterol deficiency, leads to fungal cell death. Unlike azole antifungals that inhibit a later step in ergosterol synthesis, terbinafine’s unique mechanism makes it fungicidal against dermatophytes and fungistatic against some yeasts.

Indications and Approved Uses

Lamisil is indicated for a variety of dermatophyte infections. The most common use is for tinea pedis (athlete’s foot), tinea cruris (jock itch), and tinea corporis (ringworm). It is also highly effective for onychomycosis (fungal nail infections), which often require longer treatment durations. Topical formulations (cream, gel, spray, solution) are available for localized skin infections, while oral tablets are reserved for more extensive or resistant cases, particularly nail infections. In many countries, oral terbinafine is considered a first-line therapy for dermatophyte onychomycosis due to its high cure rates and relatively short treatment course (typically 6–12 weeks for fingernails and 12–24 weeks for toenails, though drug levels persist in nails for months after cessation). Additionally, Lamisil is sometimes used off-label for other mycoses such as tinea capitis (scalp ringworm) in children and adults, although griseofulvin or newer agents may be preferred in certain cases.

Pharmacokinetics and Dosage

When taken orally, terbinafine is well absorbed (over 70% bioavailability) and extensively distributed to body tissues, including skin and nails. It is highly lipophilic and keratinophilic, concentrating in the stratum corneum, hair, and nail plates. The drug is metabolized in the liver via multiple cytochrome P450 enzymes (primarily CYP2D6) and excreted largely in urine. The standard oral dose for adults with onychomycosis is 250 mg once daily. For children, dosing is weight-based. Topical preparations are applied once or twice daily for 1–4 weeks depending on the infection site. Therapy duration varies: tinea pedis may require 1 week of topical treatment, while nail infections demand several months of oral therapy due to slow nail growth.

Efficacy and Clinical Considerations

Clinical studies demonstrate that oral terbinafine achieves mycological cure rates of 70–80% for toenail onychomycosis and higher for fingernail infections. It is generally more effective than griseofulvin and comparable to newer triazoles like itraconazole, but with a shorter treatment duration and fewer drug interactions. However, treatment success depends on patient adherence and nail regrowth. For skin infections, topical Lamisil is highly effective, with cure rates exceeding 80% in most trials. Resistance to terbinafine is rare but has been reported, particularly in some dermatophyte strains with squalene epoxidase mutations.

Safety and Side Effects

Overall, terbinafine is well tolerated. The most common adverse effects are gastrointestinal (nausea, diarrhea, dyspepsia), headache, and rash. Taste disturbance (dysgeusia) is a distinctive but uncommon side effect, often reversible after discontinuation. More serious but rare events include hepatotoxicity, severe skin reactions (e.g., Stevens-Johnson syndrome), and blood dyscrasias (neutropenia, agranulocytosis). Liver enzyme monitoring is recommended before and during oral therapy, especially in patients with pre-existing liver disease or those on hepatotoxic medications. Because terbinafine inhibits CYP2D6, it can increase plasma levels of drugs metabolized by this enzyme (e.g., tricyclic antidepressants, beta-blockers, some antipsychotics, and codeine). Patients taking such medications should be monitored for toxicity.

Contraindications and Precautions

Lamisil is contraindicated in patients with chronic or active liver disease, and in those with a history of allergic reactions to terbinafine. It should be used with caution in patients with renal impairment (creatinine clearance <50 mL/min) as drug accumulation may occur. Pregnancy category B indicates no evidence of risk in animal studies, but human data are limited; thus, oral terbinafine is generally avoided during pregnancy unless clearly needed. Topical formulations are considered safer during pregnancy and lactation. For nursing mothers, systemic absorption is minimal with topical use, but oral therapy is not recommended.

Drug Interactions

As noted, terbinafine is a potent inhibitor of CYP2D6. It also slightly inhibits CYP3A4, though less significantly than azole antifungals. Concomitant use with rifampin increases terbinafine clearance, potentially reducing efficacy. Cimetidine decreases clearance, leading to higher drug levels. Patients on warfarin should have INR monitored, as isolated reports of altered anticoagulation exist. Otherwise, terbinafine has fewer drug-drug interactions than azoles, which is an advantage in polypharmacy patients.

Special Populations

In pediatric patients, oral terbinafine is approved for tinea capitis in many countries, with short courses of 4–6 weeks. Safety and efficacy in children under 2 years have not been established. In the elderly, renal function should be assessed before starting oral therapy. Weight-based dosing is important for those with low body mass.

Comparative Role in Therapy

Lamisil remains a cornerstone for dermatophyte infections, especially onychomycosis. Its fungicidal action, high tissue penetration, and reasonable safety profile make it preferable to many alternatives. However, for candidal infections, azoles (e.g., fluconazole) are more appropriate. For superficial tinea, topical terbinafine is often sufficient and avoids systemic risks. In cases of terbinafine resistance or intolerance, alternatives include itraconazole, fluconazole, griseofulvin, or newer agents like efinaconazole topical for nails.

Conclusion

Lamisil (terbinafine) is a highly effective antifungal with a well-understood mechanism and favorable safety profile when used appropriately. Its primary role in treating dermatophyte infections—particularly onychomycosis—has been established over decades of clinical use. With proper patient selection, monitoring, and 500mg offerta disponibile €0.36 — Disulfiram, click here., awareness of drug interactions, terbinafine remains a valuable tool in dermatology and primary care. Emerging resistance necessitates ongoing surveillance, but for now, Lamisil continues to be a first-line systemic antifungal for dermatophyte nail and skin infections.